Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms.

Nature communications·2026

Same author

Plasmacytic markers as immunotherapeutic targets for primary CD20-negative aggressive B-cell lymphomas.

British journal of haematology·2026

Same author

Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas.

Cancers·2026

Same author

Immunohistochemical Analysis of Potential Therapeutic Targets PRAME, FOLR1, and CLDN18.2 in Salivary Gland Carcinomas.

Cancer medicine·2026

Same author

Positive net antiviral benefit of bexarotene against patient-derived archetype and rearranged BK polyomavirus isolates.

Antiviral research·2026

Same author

Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.

JAMA internal medicine·2025

Same journal

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Oncoimmunology·2026

Same journal

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.

Oncoimmunology·2026

Same journal

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026

Same journal

Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity.

Oncoimmunology·2026

Same journal

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026

Same journal

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 21, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

RIPK3-a predictive marker for personalized immunotherapy?

¹Institute of Virology, Saarland University , Homburg/Saar, Germany.

|May 4, 2016

Summary

This summary is machine-generated.

Identifying patients for cancer immunotherapy is challenging. Research shows the necroptosis regulator RIPK3 in cancer cells predicts response to PolyIC immunotherapy in cervical cancer models.

Keywords:

Cancer Dendritic cells Immune response RIPK3 dsRNA

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Related Experiment Videos

Last Updated: Mar 21, 2026

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

Cancer immunotherapy offers promising treatment strategies but lacks reliable biomarkers for patient selection.
Predicting treatment efficacy remains a significant hurdle in optimizing patient outcomes.

Purpose of the Study:

To identify predictive biomarkers for cancer immunotherapy response.
To investigate the role of necroptosis regulators in immunotherapy efficacy using a cervical cancer model.

Main Methods:

Utilized a cervical cancer model to study PolyIC-induced immunogenicity.
Assessed the dependency of PolyIC-driven immunogenicity on the RIPK3 (receptor-interacting protein kinase 3) pathway in neoplastic cells.

Main Results:

Demonstrated that PolyIC-driven immunogenicity is strictly dependent on RIPK3 within cancer cells.
Established a clear link between RIPK3 expression/function and immunotherapy response in the studied model.

Conclusions:

RIPK3 is a crucial mediator of PolyIC-induced immunogenicity in cervical cancer.
RIPK3 emerges as a potential novel predictive biomarker for personalizing cancer immunotherapy strategies.